Background: Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated the activity of targeted therapies in metastatic CDC. Patients and Methods: We evaluated a cohort of 384 consecutive patients with metastatic renal cell carcinoma (mRCC). The characteristics of patients with CDC were compared against those of the remaining cohort. All patients with CDC were treated with targeted therapies. Results: Thirteen patients with advanced CDC were referred to our Center (incidence: 3.4% of all mRCC). Median age was 57 and 62 years in the CDC and non-CDC groups, respectively. The overall disease control in the CDC population was 23%, and median overall survival was 4 (95% confidence interval(CI)=2.4-5.6) months. Three patients obtained a satisfying response (disease control lasting 6-33 months). Conclusion: CDC has a poor prognosis compared to non-CDC renal cell carcinoma. Treatment for CDC represents a future challenge and targeted therapies may play a role in selected cases.

Treatment of collecting duct carcinoma : current status and future perspectives / G. Procopio, I. Testa, R. Iacovelli, P. Grassi, E. Verzoni, E. Garanzini, M. Colecchia, T. Torelli, F. De Braud. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 34:2(2014 Feb), pp. 1027-1030.

Treatment of collecting duct carcinoma : current status and future perspectives

I. Testa
Secondo
;
E. Verzoni;F. De Braud
Ultimo
2014-02

Abstract

Background: Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated the activity of targeted therapies in metastatic CDC. Patients and Methods: We evaluated a cohort of 384 consecutive patients with metastatic renal cell carcinoma (mRCC). The characteristics of patients with CDC were compared against those of the remaining cohort. All patients with CDC were treated with targeted therapies. Results: Thirteen patients with advanced CDC were referred to our Center (incidence: 3.4% of all mRCC). Median age was 57 and 62 years in the CDC and non-CDC groups, respectively. The overall disease control in the CDC population was 23%, and median overall survival was 4 (95% confidence interval(CI)=2.4-5.6) months. Three patients obtained a satisfying response (disease control lasting 6-33 months). Conclusion: CDC has a poor prognosis compared to non-CDC renal cell carcinoma. Treatment for CDC represents a future challenge and targeted therapies may play a role in selected cases.
bellini disease; collecting ducts carcinoma; renal carcinoma; targeted therapy; adult; aged; aged, 80 and over; angiogenesis inhibitors; antineoplastic agents; carcinoma, renal cell; cohort studies; humans; kidney neoplasms; middle aged; neovascularization, pathologic; niacinamide; phenylurea compounds; pyrimidines; sirolimus; sulfonamides
Settore MED/06 - Oncologia Medica
http://ar.iiarjournals.org/content/34/2/1027.abstract
Article (author)
File in questo prodotto:
File Dimensione Formato  
1027.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 80.74 kB
Formato Adobe PDF
80.74 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/425878
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 21
social impact